Interim commissioning guidance: implementation of the NICE technology appraisal TA1026 and the NICE funding variation for tirzepatide (Mounjaro®) for the management of obesity

Document first published:
Page updated:
Topic:
,
Publication type:

This interim commissioning guidance outlines NHS England’s approach to implementing tirzepatide (Mounjaro®) into the weight management pathway. The full guidance will be issued after an evaluation by NICE of the initial 3 year rollout.

Document

Interim commissioning guidance: implementation of the NICE technology appraisal TA1026 and the NICE funding variation for tirzepatide (Mounjaro®) for the management of obesity

Interim commissioning guidance: implementation of the NICE technology appraisal TA1026 and the NICE funding variation for tirzepatide (Mounjaro®) for the management of obesity

  • PDF
  • 351 KB
  • 20 pages

Summary

Published 27 March 2025.